JG
VKTX icon

Jefferies Group’s Viking Therapeutics VKTX Stock Holding History

Jefferies Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-24,000
Closed -$135K – 2020
2020
Q4 		$135K Buy
+24,000
New +$145K ﹤0.01% 1426
2020
Q3 		– Sell
-50,000
Closed -$361 – 1561
2020
Q2 		$361 Hold
50,000
– – ﹤0.01% 981
2020
Q1 		$234K Buy
+50,000
New +$307K ﹤0.01% 1627
2019
Q2 		– Sell
-85,400
Closed -$849K – 2880
2019
Q1 		$849K Buy
+85,400
New +$715K 0.01% 1345
2018
Q4 		– Sell
-116,200
Closed -$2.02M – 2605
2018
Q3 		$2.02M Buy
116,200
+24,200
+26% +$288K 0.01% 972
2018
Q2 		$873K Buy
+92,000
New +$612K ﹤0.01% 1338

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group's VKTX Position: Q2 2020 in Review

Jefferies Group sold out of Viking Therapeutics (VKTX) in Q2 2020, closing a stake of 1,627 shares — an estimated $10.8K sold.

Jefferies Group first reported a position in VKTX in Q1 2018 and held it in 8 quarters. The position peaked at $453K in Q2 2019. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2020.

  • Jefferies Group reported no remaining Viking Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Jefferies Group sold 1,627 Viking Therapeutics shares in Q2 2020, an estimated $10.8K.
  • Jefferies Group first reported a position in Viking Therapeutics in Q1 2018 and held it in 8 quarters.
  • Jefferies Group's Viking Therapeutics position peaked at $453K in Q2 2019.
  • 138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2020.

Based on Jefferies Group's 13F filing for Q2 2020, filed 14 Aug 2020.